Skip to main content

Advertisement

Table 1 Clinicopathologic characteristics of the 672 patients with metastatic nasopharyngeal carcinoma (NPC)

From: Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma

Characteristic Total (cases) Deaths [cases (%)] Unadjusted HR (95 % CI) P value
Total 672 458   
Gender     
Male 546 371 (67.9) Reference 0.700
Female 126 87 (69.0) 1.05 (0.83, 1.32)  
Age (years)     
<46 316 213 (67.4) Reference 0.124
≥46 356 245 (68.8) 1.16 (0.96, 1.39)  
T stage*     
T1-2 273 184 (67.4) Reference 0.975
T3-4 399 274 (68.7) 1.00 (0.83, 1.20)  
N stage*     
N0-1 273 172 (63.0) Reference <0.001
N2-3 399 286 (71.7) 1.42 (1.18, 1.72)  
Metastasis at presentation     
Absent 375 261 (69.6) Reference 0.825
Present 297 197 (66.3) 0.98 (0.81, 1.18)  
Number of metastatic lesions     
1 105 51 (48.6) Reference <0.001
≥2 567 407 (71.8) 2.06 (1.54, 2.77)  
Bone metastasis     
Absent 280 196 (70.0) Reference 0.862
Present 392 262 (66.8) 1.02 (0.85, 1.22)  
Liver metastasis     
Absent 443 283 (63.9) Reference <0.001
Present 229 175 (76.4) 1.62 (1.34, 1,95)  
Lung metastasis     
Absent 462 309 (66.9) Reference 0.847
Present 210 149 (71.0) 0.98 (0.81, 1.19)  
Extraregional lymph node metastasis     
Absent 497 328 (66.0) Reference 0.060
Present 175 130 (74.3) 1.22 (0.99, 1.49)  
EBV VCA/IgA     
<1:80 80 48 (60.0) Reference 0.413
1:80–1:320 395 270 (68.4) 1.15 (0.84, 1.56)  
≥1:640 197 140 (71.1) 1.17 (0.85, 1.63)  
EBV EA/IgA     
<1:10 128 84 (65.6) Reference 0.385
1:10–1:20 216 149 (69.0) 0.97 (0.74, 1.27)  
≥1:40 328 225 (68.6) 0.91 (0.71, 1.16)  
Lymphocyte count (× 109/L)     
<1.390 340 250 (73.5) Reference 0.002
≥1.390 332 208 (62.7) 0.75 (0.63, 0.90)  
Monocyte count (× 109/L)     
<0.665 428 263 (61.4) Reference <0.001
≥0.665 244 195 (80.0) 2.17 (1.80,2.62)  
LMR     
<2.475 335 269 (80.3) Reference <0.001
≥2.475 337 189 (56.1) 0.45 (0.37, 0.54)  
  1. HR, hazard ratio; CI, confidence interval; EBV, Epstein-Barr virus; VCA/IgA, immunoglobulin A against viral capsid antigen; EA/IgA, immunoglobulin A against early antigen; LMR, lymphocyte-to-monocyte ratio. *The American Joint Committee on Cancer (AJCC) 2002 system was used for staging at the diagnosis of NPC